Navigation Links
Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
Date:11/29/2011

o add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's expectations that data from the first Phase 3 trial of OMS302 will be available during the first quarter of 2012, that Omeros will initiate a second Phase 3 trial of OMS302 following discussions with regulators, that Omeros will be poised to file marketing applications as soon as possible following receipt of OMS302 Phase 3 clinical data , and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 ... has announced the addition of the ... to their offering.      (Logo: ... of chromosomes using molecular biology to understand ... chromosomes. It plays a crucial role in ...
(Date:9/18/2014)... , Sept. 18, 2014  Low T ... committee meeting in Hyattsville, Maryland ... to assess the proper patient population for testosterone ... cardiovascular risk associated with TRT. Examining recent claims from ... found that "available epidemiological studies do not provide ...
(Date:9/18/2014)... CITY, Kan. , Sept. 18, 2014 /PRNewswire/ ... a pet therapeutics company focused on licensing, developing ... today announced the full exercise of the underwriters, ... stock in connection with the company,s previously announced ...  All of the shares are being offered by ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
... ,, ORLANDO, Fla. , May 17 The ... RunE2E and hosted in a secure, private cloud enabled by Freudenberg ... Cryo-Cell International, Inc., a pioneering healthcare company specializing in stem cell ... , ...
... May 17 Xenon Pharmaceuticals Inc. is pleased to announce today ... President, Research and Development. , ... "We are delighted to welcome Tarek to the Xenon team," commented ... R&D executive whose experience in discovering products, a number of which are ...
Cached Medicine Technology:RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 2RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 3RunE2E and Freudenberg IT Create Customer Value Through Implementation of SAP® CRM in Hosted, Private Cloud 4Xenon Announces Appointment of EVP, Research & Development 2
(Date:9/18/2014)... Memorial Cardiac and Vascular Institute ... by performing the first ever, adult heart transplant in ... Organ Sharing) approval to launch the adult heart transplant ... programs in South Florida. , The skilled cardiac ... Medical Director of the Adult Heart Transplant and ...
(Date:9/18/2014)... to diverse communities may boost infants, social learning, according ... in the park or supermarket could help children be ... different from them, researchers found. "Research has ... interacting with and learning from people who are different ... psychology professor, said in a university news release. ...
(Date:9/18/2014)... Reinberg HealthDay Reporter , THURSDAY, Sept. ... outbreak in West Africa is starting to spread faster than ever, ... cases of the deadly viral infection were reported in just one ... than 5,300, with roughly half of those reported in the past ... deaths now tops 2,600. WHO has estimated that as many ...
(Date:9/18/2014)... It’s been just a few short weeks ... bunion splint to website visitors, but already the response has ... absolutely delighted. It is perfect and I find it sooo ... THANK YOU FOR LISTENING!!!" Another user compared the original ... used to slip to the end of my toe. Now ...
(Date:9/18/2014)... 18, 2014 It is that time of ... and wellness. Once again, Evensong Spa at ... offering three services at a special $50 rate Oct. 20 ... Marcus Hotels & Resorts , is the only Wisconsin ... Americans to embrace health and wellness by experiencing affordable spa ...
Breaking Medicine News(10 mins):Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 2Health News:New Ebola Cases Top 700 in Just One Week, Officials Report 3Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3
... By Jenifer Goodwin HealthDay Reporter , ... genetic variants implicated in ADHD (attention-deficit/hyperactivity disorder) overlap with ... in autism, a new study finds. The ... ADHD, autism and other neuropsychiatric disorders sometimes have symptoms ...
... teenagers prefer social media over the telephone, you may want ... involved in research studies. When 188 ninth-11th graders in ... be contacted about their participation in a Georgia Health Sciences ... contact via cell and/or land line with a recorded message ...
... WEDNESDAY, Aug. 10 (HealthDay News) -- The breast cancer drug ... especially those with a history of heart disease and/or diabetes, ... of 45 women, ages 70 to 92, who were treated ... percent) of them developed heart problems caused by the drug. ...
... Aug. 10 (HealthDay News) -- Eating red meat -- especially ... of type 2 diabetes, a new study warns. It ... by replacing red meat with healthier proteins, such as nuts, ... Public Health researchers looked at 20 years of data from ...
... have had so far with the much-heralded field of nanotechnology ... of Chemical & Engineering News (C&EN), the American ... science of ultra-small particles so tiny that 50,000 could ... come when sunbathers, golfers, bikers and others slather on sunscreen ...
... DURHAM, N.H. A University of New Hampshire researcher ... pro-eugenic beliefs manipulated his research findings so he could ... mentally and morally "unfit" people. Benjamin Harris, professor ... has found that Yale psychologist Arnold Gesell manipulated the ...
Cached Medicine News:Health News:ADHD, Autism May Sometimes Share Gene Mutations 2Health News:ADHD, Autism May Sometimes Share Gene Mutations 3Health News:Telephone trumps social media when communicating with teens about research 2Health News:Breast Cancer Drug Raises Risk of Heart Problems in Older Women: Study 2Health News:Daily Hot Dog May Feed Diabetes Risk: Study 2Health News:UNH researcher discovers research manipulated to support pro-eugenic beliefs 2Health News:UNH researcher discovers research manipulated to support pro-eugenic beliefs 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: